SK4 calcium-activated potassium channels activated by sympathetic nerves enhances atrial fibrillation vulnerability in a canine model of acute stroke.
Atrial fibrillation
Cardiovascular system
Circulatory system
Intermediate-conductance KCa channels
Internal medicine
Laboratory medicine
Neuroscience
Pharmacology
Stroke
Sympathetic nerve
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
24
12
2019
revised:
24
02
2020
accepted:
01
05
2020
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
19
5
2020
Statut:
epublish
Résumé
New-onset atrial fibrillation (AF) is common in patients with acute stroke (AS). Studies have shown that intermediate-conductance calcium-activated potassium channel channels (SK4) play an important role in cardiomyocyte automaticity. The aim of this study was to investigate the effects of SK4 on AF vulnerability in dogs with AS. Eighteen dogs were randomly divided into a control group, AS group and left stellate ganglion ablation (LSGA) group. In the control group, dogs received craniotomy without right middle cerebral artery occlusion (MCAO). AS dogs were established using a cerebral ischemic model with right MCAO. LSGA dogs underwent MCAO, and LSGA was performed. Three days later, the dispersion of the effective refractory period (dERP) and AF vulnerability in the AS group were significantly increased compared with those in the control group and LSGA group. However, no significant difference in dERP and AF vulnerability was found between the control group and the LSGA group. The SK4 inhibitor (TRAM-34) completely inhibited the inducibility of AF in AS dogs. SK4 expression and levels of noradrenaline (NE), β1-AR, p38 and c-Fos in the atrium were higher in the AS dogs than in the control group or LSGA group. However, no significant difference in SK4 expression or levels of NE, β1-AR, p38 and c-Fos in the left atrium was observed between the control group and LSGA group. SK4 plays a key role in AF vulnerability in a canine model with AS. The effects of LSGA on AF vulnerability were associated with the p38 signaling pathways.
Sections du résumé
BACKGROUND
BACKGROUND
New-onset atrial fibrillation (AF) is common in patients with acute stroke (AS). Studies have shown that intermediate-conductance calcium-activated potassium channel channels (SK4) play an important role in cardiomyocyte automaticity. The aim of this study was to investigate the effects of SK4 on AF vulnerability in dogs with AS.
EXPERIMENTAL
METHODS
Eighteen dogs were randomly divided into a control group, AS group and left stellate ganglion ablation (LSGA) group. In the control group, dogs received craniotomy without right middle cerebral artery occlusion (MCAO). AS dogs were established using a cerebral ischemic model with right MCAO. LSGA dogs underwent MCAO, and LSGA was performed.
RESULTS
RESULTS
Three days later, the dispersion of the effective refractory period (dERP) and AF vulnerability in the AS group were significantly increased compared with those in the control group and LSGA group. However, no significant difference in dERP and AF vulnerability was found between the control group and the LSGA group. The SK4 inhibitor (TRAM-34) completely inhibited the inducibility of AF in AS dogs. SK4 expression and levels of noradrenaline (NE), β1-AR, p38 and c-Fos in the atrium were higher in the AS dogs than in the control group or LSGA group. However, no significant difference in SK4 expression or levels of NE, β1-AR, p38 and c-Fos in the left atrium was observed between the control group and LSGA group.
CONCLUSION
CONCLUSIONS
SK4 plays a key role in AF vulnerability in a canine model with AS. The effects of LSGA on AF vulnerability were associated with the p38 signaling pathways.
Identifiants
pubmed: 32420493
doi: 10.1016/j.heliyon.2020.e03928
pii: S2405-8440(20)30773-8
pii: e03928
pmc: PMC7215192
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e03928Informations de copyright
© 2020 The Author(s).
Références
Pacing Clin Electrophysiol. 2015 Jan;38(1):107-14
pubmed: 25224585
JACC Clin Electrophysiol. 2015 Mar-Apr;1(1-2):1-13
pubmed: 26301262
Acta Pharmacol Sin. 2016 Jan;37(1):82-97
pubmed: 26725737
J Cell Biochem. 2018 Jan;119(1):1204-1214
pubmed: 28722223
EMBO Mol Med. 2017 Apr;9(4):415-429
pubmed: 28219898
Circ Res. 2014 Apr 25;114(9):1500-15
pubmed: 24763467
Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E155-63
pubmed: 20978230
PLoS One. 2013 May 27;8(5):e64611
pubmed: 23724069
Hypertension. 2015 Nov;66(5):1042-9
pubmed: 26418021
Heart Rhythm. 2013 Jun;10(6):910-5
pubmed: 23357541
Stroke. 2004 Sep;35(9):2094-8
pubmed: 15272134
Exp Clin Cardiol. 2013 Winter;18(1):38-42
pubmed: 24294036
Cardiovasc Res. 2014 Jul 1;103(1):156-67
pubmed: 24817686
Biochem Pharmacol. 2013 May 15;85(10):1486-94
pubmed: 23500546
J Neurosci Rural Pract. 2015 Apr-Jun;6(2):145-50
pubmed: 25883469
Europace. 2015 Apr;17(4):647-54
pubmed: 25349225
J Clin Diagn Res. 2017 Feb;11(2):OC28-OC31
pubmed: 28384912
J Auton Nerv Syst. 1995 Jun 25;53(2-3):205-14
pubmed: 7560757
Circ Arrhythm Electrophysiol. 2017 Oct;10(10):
pubmed: 29018164
Circ Arrhythm Electrophysiol. 2018 May;11(5):e005945
pubmed: 29700056
Circulation. 2000 Mar 14;101(10):1185-91
pubmed: 10715267
Cardiovasc Pathol. 2008 Sep-Oct;17(5):303-8
pubmed: 18692409
Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2714-23
pubmed: 16055520
PLoS One. 2013 Nov 06;8(11):e78218
pubmed: 24223140
Neurology. 2016 Nov 8;87(19):2034-2042
pubmed: 27733570
Eur J Pharmacol. 2008 Nov 12;597(1-3):81-5
pubmed: 18804461
J Cereb Blood Flow Metab. 2011 Dec;31(12):2363-74
pubmed: 21750563
Cell Signal. 2010 Apr;22(4):584-9
pubmed: 19932173